BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 28604160)

  • 1. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basic background for adjuvant immunotherapy].
    Seya T
    Nihon Rinsho; 2012 Dec; 70(12):2059-65. PubMed ID: 23259375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvants for cancer vaccines.
    Dubensky TW; Reed SG
    Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision nanoscale patterning of TLR ligands for improved cancer immunotherapy.
    Tseng CY; Murtada F; Chou LYT
    Cell Rep Methods; 2024 May; 4(5):100782. PubMed ID: 38772343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.
    de Brito CA; Goldoni AL; Sato MN
    Immunotherapy; 2009 Sep; 1(5):883-95. PubMed ID: 20636030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor ligands energize peptide vaccines through multiple paths.
    Celis E
    Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
    Kobiyama K; Ishii KJ
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine adjuvants as potential cancer immunotherapeutics.
    Temizoz B; Kuroda E; Ishii KJ
    Int Immunol; 2016 Jul; 28(7):329-38. PubMed ID: 27006304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvants and autoimmunity.
    Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
    Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy and nanomedicine.
    Sheng WY; Huang L
    Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
    Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():615240. PubMed ID: 33679703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
    Vermaelen K
    Front Immunol; 2019; 10():8. PubMed ID: 30723469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of chemokines as adjuvants for vaccine immunotherapy.
    Mohan T; Zhu W; Wang Y; Wang BZ
    Immunobiology; 2018; 223(6-7):477-485. PubMed ID: 29246401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.
    Zhang W; An M; Xi J; Liu H
    Bioconjug Chem; 2017 Jul; 28(7):1993-2000. PubMed ID: 28644608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Toll-like receptors: recognition receptors of the innate immune system and target structures for therapeutical intervention].
    Kabelitz D
    Med Monatsschr Pharm; 2012 Jul; 35(7):238-44. PubMed ID: 22852274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
    Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
    Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.